• In the past few days, DaVita reported strong first-quarter 2026 results, with higher revenues, improved earnings and operating income, and raised its full-year adjusted operating income and earnings per share guidance.
• Beyond the headline beat, DaVita’s willingness to lift guidance while flagging rising patient-care and technology costs highlights management’s confidence in its cost-control and efficiency efforts.
• Next, we’ll examine how DaVita’s upgraded 2026 earnings guidance could influence the existing investment narrative around efficiency, growth, and risk.

Explore 30 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

DaVita Investment Narrative Recap

To own DaVita, you need to believe dialysis remains a durable, cash generative business where management can offset rising care and technology costs with efficiency gains and modest volume growth. The latest earnings beat and guidance raise support that thesis in the near term, and also ease some concern around the key short term catalyst of margin stability. The biggest risk remains that higher patient care and tech spending eventually outpace reimbursement and efficiency improvements, pressuring profitability.

Among recent announcements, the company’s continued share repurchases stand out alongside the strong first quarter. DaVita has bought back over 2.8 million shares for roughly US$383 million so far in 2026, after several billion dollars of prior repurchases. While this does not change the core operating story, it amplifies the impact of any improvement in earnings per share and ties directly into how investors think about near term upside from the upgraded 2026 guidance and cost control efforts.

Yet despite stronger guidance, investors should still pay close attention to rising patient care and technology costs and how these could eventually...

DaVita's narrative projects $15.7 billion revenue and $1.1 billion earnings by 2029.

Uncover how DaVita's forecasts yield a $193.71 fair value, in line with its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already banking on DaVita reaching about US$15.3 billion in revenue and roughly US$1.1 billion in earnings, so this new guidance and cost trend could either bolster that upbeat view or force a rethink, depending on how you weigh the upside from technology against the risk that those investments keep general and administrative costs higher for longer.

Explore 2 other fair value estimates on DaVita - why the stock might be worth 27% less than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your DaVita research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free DaVita research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate DaVita's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Rare earth metals are the new gold rush. Find out which 27 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.